Empowering the Next Generation of Microbial Factories through Precision Genomics and Metabolic Flux Optimization. Saccharomyces cerevisiae is no longer just a tool for traditional fermentation; it has become the premier eukaryotic chassis for the global bio-economy. CD Biosynsis provides professional Saccharomyces cerevisiae Genome Editing & Metabolic Engineering Services, combining cutting-edge CRISPR/Cas9 and CRISPRi/a systems with Adaptive Laboratory Evolution (ALE). We help our clients overcome cellular toxicity, optimize carbon flux from renewable feedstocks, and construct high-performance strains for the production of flavors, fragrances, and high-value industrial chemicals.
Get a Technical QuoteOur platform transforms S. cerevisiae into a highly efficient production host through systemic genomic rewiring and fine-tuned transcriptional control. We focus on bridging the gap between laboratory design and industrial-scale performance.
| Service Tier | Technical Strategy | Primary Application | Standard Deliverables |
|---|---|---|---|
| Tolerance Engineering | Adaptive Laboratory Evolution (ALE) | Toxic product synthesis (e.g., PEA) | Robust strains + Growth kinetic data |
| High-Efficiency Editing | CRISPR/Cas9 Scarless Integration | Biorefinery pathway assembly | Verified mutants + Sequencing reports |
| Dynamic Metabolic Tuning | CRISPRi (Interference) & CRISPRa | Flux redirection & bottleneck removal | Regulation-ready strains + qPCR data |
| Pathway Optimization | Synthetic Regulatory Elements | High-titer synthesis of bio-chemicals | High-yield chassis + Titer analysis |
1. Metabolic Network Design
2. Genomic Execution
3. Fitness Restoration (ALE)
4. Scale-up Validation
Identifying rate-limiting steps and competitive pathways using in silico modeling to design the engineering strategy.
Formal project proposal and Mutual NDA signing.
Implementing CRISPR/Cas9 for deep knockouts or scarless integration, or CRISPRi/a for dynamic flux regulation.
Application of synthetic regulatory parts to optimize pathway throughput.
Subjecting strains to long-term evolutionary pressure to enhance product tolerance and restore growth rates.
High-throughput screening of variants under simulated industrial conditions.
Final genetic verification via WGS and delivery of optimized "Cell Factory" strains ready for industrial scale-up.
Comprehensive characterization of Titer, Yield, and Rate (TYR) in bioreactor environments.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field.
PEA is a high-value fragrance ingredient, but its toxicity often limits production. By combining genome editing with ALE, benchmarks have successfully developed strains thriving under high PEA concentrations. These evolved strains maintain high metabolic activity, providing a stabilized platform for large-scale fragrance production.
(Reference: Frontiers in Microbiology, 2023)
A circular bio-economy requires yeast that can convert biorefinery sugars into raw materials. Utilizing CRISPR/Cas9, researchers rewired S. cerevisiae to ferment xylose and glucose into high-value chemicals like 1,2-propanediol. These strains exhibit high yields, demonstrating yeast as a versatile industrial biotransformation platform.
(Reference: Biotechnology Advances, 2021)
Industrial fermentation demands precise control to maximize output. Advanced CRISPRi/a systems provide a roadmap for the next generation of industrial yeast. These tools allow for the dynamic regulation of gene expression, ensuring carbon flow is redirected toward the target product at exactly the right time in the cycle.
(Reference: Frontiers in Bioengineering and Biotechnology, 2023)
Ready to engineer your high-performance industrial yeast strain?
Contact Us1. What is the advantage of ALE over rational design for tolerance engineering?
Rational design targets known genes, but ALE allows the yeast to find its own optimal solution to toxicity across its entire network. This results in far more robust strains for toxic chemicals like aromatics and solvents.
2. Can you perform edits in my proprietary industrial yeast strain?
Yes. We have extensive experience adapting our CRISPR toolkits to diversas industrial backgrounds. 我们在严格的保密协议（NDA）下工作，优化您的专属生产底盘。
3. Is the CRISPR/Cas9 machinery removed from the final production strain?
Absolutely. We use transient expression systems or specialized curing protocols to ensure no foreign Cas9 machinery remains, leaving you with a "clean" engineered product without foreign DNA footprints.
4. How do you handle the metabolic burden of multiple heterologous genes?
We use CRISPRi/a to fine-tune expression so enzymes are produced only when needed, and apply Adaptive Evolution (ALE) to select for cells that have successfully balanced their metabolic load for optimal growth.
5. What is the typical development cycle for a metabolic engineering project?
A standard comprehensive project—from initial design and CRISPR integration to ALE restoration and titer validation—typically takes 12 to 18 weeks.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.